Enter the vial size and the bacteriostatic water you added to get the concentration and the micrograms carried by each unit on a U-100 syringe. Adamax has no approved use and no stated dose, so this page does the arithmetic, not the recommendation. The compound itself is covered in the Adamax (davunetide/NAP) guide.
A 10 mg vial of Adamax reconstituted with 2 mL of bacteriostatic water gives a concentration of 5.0 mg/mL, or 50 mcg per unit on a U-100 syringe.
Defaults: 10 mg is the most common labelled vial among the Adamax tests on file, 21 Sep 2026 (28 of 37); 2 mL was chosen for simple arithmetic and is not a sourced volume. Peptigrity publishes no Adamax dose, so the dose field starts empty.
Draw the syringe up to
Enter your own amount to see the draw. Add 2 mL of water to your 10 mg vial first.
Adamax has 37 independent lab tests on file at Peptigrity, averaging 99.57% HPLC purity across the tests that report one. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Adamax lab-test records.
"Adamax" is a vendor and community label. The molecule that was actually researched is davunetide (NAP), a synthetic octapeptide (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from a small active region of ADNP, activity-dependent neuroprotective protein. Davunetide reached the clinic only as an intranasal formulation (developed as AL-108/AL-208). Its Phase 2/3 trial in progressive supranuclear palsy failed to meet its primary efficacy endpoint and the program was discontinued; an earlier Phase 2 study in amnestic mild cognitive impairment produced only mixed, inconsistent signals. Research-grade vials sold as Adamax are not that clinical product, and the compound page declines to state a dose.
The table summarises what the Adamax compound page states (last updated August 2026).
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | A synthetic octapeptide (NAPVSIPQ) from ADNP, researched for microtubule stabilization | Chemical identity |
| Human studies? | Phase 2/3 in progressive supranuclear palsy — primary endpoint not met, program discontinued | Phase 2/3 — failed primary endpoint |
| Clinical formulation? | Intranasal only (AL-108/AL-208); no route stated for research-grade material | Clinical record |
| An approved dose? | Not approved for any indication; no active clinical development program (as of August 2026) | None |
| A research dose? | None — "Does Peptigrity recommend an Adamax dose? No." | None — declined |
One practical consequence: the compound page is explicit that davunetide's tolerability was established for the intranasal formulation under trial monitoring and does not transfer to research-grade material sold as Adamax, which carries none of that human safety characterization. The arithmetic below converts the milligrams on a label into units; it does not reproduce the clinical formulation, and it cannot confirm that the vial holds davunetide at all. Only a mass-spectrometry identity result on a certificate can.
The table converts reference quantities to syringe units at the default of 5.0 mg/mL (10 mg of Adamax in 2 mL), and counts how many draws of each a vial holds. Every row is arithmetic, not a dose: read the units for the amount you already intend to measure.
| Quantity | Draw at 5.0 mg/mL | Volume | Draws from a 5 mg vial | Draws from a 10 mg vial |
|---|---|---|---|---|
| 50 mcg | 1.0 units | 0.01 mL | 100 | 200 |
| 100 mcg | 2.0 units | 0.02 mL | 50 | 100 |
| 250 mcg | 5.0 units | 0.05 mL | 20 | 40 |
| 500 mcg | 10.0 units | 0.10 mL | 10 | 20 |
| 1 mg | 20.0 units | 0.20 mL | 5 | 10 |
The same Adamax quantity lands on a different mark depending on how much water went into the vial. Read down the column for the concentration you actually mixed; a units figure carried across from another column is simply wrong.
| Quantity | At 10 mg/mL (10 mg + 1 mL) | At 5.0 mg/mL (10 mg + 2 mL) | At 2.0 mg/mL (10 mg + 5 mL) |
|---|---|---|---|
| 50 mcg | 0.5 units | 1.0 units | 2.5 units |
| 100 mcg | 1.0 units | 2.0 units | 5.0 units |
| 250 mcg | 2.5 units | 5.0 units | 12.5 units |
| 500 mcg | 5.0 units | 10.0 units | 25.0 units |
| 1 mg | 10.0 units | 20.0 units | 50.0 units |
Every cell is the same arithmetic: units = (quantity in mg ÷ concentration in mg/mL) × 100 on a U-100 syringe. More water spreads the same mass over more units, which is the fix when a small quantity would otherwise sit at two or three units, where a one-unit misread is a large error.
Each Adamax vial holds as many draws as its labelled mass divided by the quantity per draw; the water volume changes nothing about it. The grid counts draws, not weeks — this page states no frequency.
| Vial size | At 50 mcg | At 100 mcg | At 250 mcg | At 500 mcg | At 1 mg |
|---|---|---|---|---|---|
| 5 mg | 100 | 50 | 20 | 10 | 5 |
| 10 mg | 200 | 100 | 40 | 20 | 10 |
The labelled mass is not a guarantee of the mass in your vial: net content is a separate measurement from purity, and certificates on file often measure a few percent above or below the label.
No label sets a diluent volume for research-grade Adamax, and the compound page states none, so the volume is a choice. The one decision with real consequences is resolution: a small quantity drawn from a strong solution sits at one or two units, where a one-unit misread is a large error, and the fix is more water. The technique is covered once, elsewhere: reconstituting peptides step by step and the bacteriostatic water guide. Storage and in-use guidance there is general peptide guidance, not an Adamax-specific finding.
Davunetide is not approved for any indication and remains in research contexts. The Phase 2/3 progressive supranuclear palsy program by Allon Therapeutics was discontinued after the primary efficacy endpoint was not met, no subsequent sponsor has resumed clinical development, and no active clinical development program exists as of August 2026. Adamax (davunetide) is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption.
Independent test records: Adamax lab tests. Tracked prices: Adamax price per milligram. Related compounds: cognitive enhancement and neuroprotection peptides.
It depends on the concentration. At the page default of 5 mg/mL (a 10 mg vial with 2 mL of water), each unit on a U-100 syringe carries 50 mcg, so 250 mcg is 5 units (0.05 mL). With 5 mL in the same vial (2 mg/mL) it is 12.5 units. A units figure quoted without a concentration cannot be used.
There isn't one. Adamax is not approved for human consumption, davunetide failed its Phase 2/3 efficacy endpoint in its lead indication, and the only human data is for an intranasal clinical formulation that research-grade vials are not. Peptigrity does not recommend a dose; this calculator converts a quantity you already have in mind into syringe units.
Adamax is a vendor and community label. The molecule that was researched is davunetide (NAP), which reached the clinic only as an intranasal formulation, developed as AL-108/AL-208. Research-grade vials sold as Adamax are not that clinical product, so their identity and contents should be independently verified.
No. The Phase 2/3 trial in progressive supranuclear palsy, run by Allon Therapeutics, failed to meet its primary efficacy endpoint and the program was discontinued. An earlier Phase 2 study in amnestic mild cognitive impairment produced only mixed, inconsistent cognitive signals that did not establish efficacy.